(Q37273477)

19 August 2017

Two doses of humanized anti-CD25 antibody in renal transplantation: a preliminary comparative study (English)

1 reference

19 August 2017

7

Bohua Li

1 reference

19 August 2017

6

Weizhu Qian

1 reference

19 August 2017

8

Dapeng Zhang

1 reference

19 August 2017

12

Yajun Guo

1 reference

19 August 2017

4

Birong Lin

1 reference

19 August 2017

Jing Li

1

1 reference

19 August 2017

Xinyan Li

2

1 reference

19 August 2017

Min Tan

3

1 reference

19 August 2017

Sheng Hou

5

1 reference

19 August 2017

Bo Zhou

9

1 reference

19 August 2017

Hao Wang

10

1 reference

19 August 2017

Tongyu Zhu

11

1 reference

19 August 2017

1 January 2009

1 reference

19 August 2017

Monoclonal Antibodies

1 reference

19 August 2017

1

1 reference

19 August 2017

1

1 reference

19 August 2017

49-55

1 reference

Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function

19 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715186

The use of daclizumab as induction therapy in combination with tacrolimus and mycophenolate mofetil in recipients with previous transplants

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715186

Phase II FK 506 multicenter concentration control study: one-year follow-up.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715186

A novel three-dose regimen of daclizumab in liver transplant recipients with hepatitis C: a pharmacokinetic and pharmacodynamic study

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715186

Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715186

Two doses of daclizumab in conjunction with low-dose cyclosporine, mycophenolate mofetil and steroids resulted in a low incidence of acute rejection after renal transplantation

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715186

IL-2 receptor blockers in liver transplantation: initial experience with daclizumab in Chile

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715186

The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715186

Pharmacokinetic and pharmacodynamic studies of one or two doses of daclizumab in renal transplantation

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715186

Daclizumab induction/tacrolimus sparing: a randomized prospective trial in renal transplantation

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715186

A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas tran

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715186

A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715186

Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study

3 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.4161%2FMABS.1.1.7399

Determination of humanized anti-Tac in human serum by a sandwich enzyme linked immunosorbent assay

21 January 2018

1 reference

12 December 2020

Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection. The Mycophenolate Mofetil Renal Refractory Rejection Study Group

1 reference

12 December 2020

Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group

1 reference

12 December 2020

Daclizumab: outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study Groups

1 reference

12 December 2020

Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group

1 reference

12 December 2020

The safety and efficacy of a two-dose daclizumab (zenapax) induction therapy in liver transplant recipients

1 reference

12 December 2020

Pharmacokinetics, pharmacodynamics, and immunodynamics of daclizumab in a two-dose regimen in liver transplantation

1 reference

12 December 2020

Identifiers

DOI

10.4161/MABS.1.1.7399

1 reference

19 August 2017

1 reference

19 August 2017

PubMed publication ID

20046574

1 reference